As of Mar 13, 2019 Arcturus Therapeutics LTD. – Ordinary Shares (NASDAQ:ARCT) Shorts Decreased By 34%

Change of 34% for Arcturus Therapeutics LTD. – Ordinary Shares (NASDAQ:ARCT)’s shorted shares was registered. In March was published ARCT’s total 59,600 shorted shares by FINRA. The down change of 34% from 90,300 shares was reported. Arcturus Therapeutics LTD. – Ordinary Shares (NASDAQ:ARCT) has 33,500 shares average volume. It’ll cost 2 days for ARCT to restore its former position. 0.91% is Arcturus Therapeutics LTD. – Ordinary Shares float short.

Ticker’s shares touched $4.9 during the last trading session after 4.26% change.Currently Arcturus Therapeutics Ltd. is downtrending after 7.96% change in last March 13, 2018. ARCT has 10,495 shares volume. The stock underperformed the S&P500 by 12.33%.

Arcturus Therapeutics Ltd. operates as an RNA medicines company.The firm is valued at $52.31 million. The Company’s RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.Currently it has negative earnings. The firm owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries.

For more Arcturus Therapeutics Ltd. (NASDAQ:ARCT) news published recently go to: Seekingalpha.com, Seekingalpha.com, Globenewswire.com, Globenewswire.com or Streetinsider.com. The titles are as follows: “Arbutus Biopharma: The Good, The Bad, And The Ugly – Seeking Alpha” published on October 09, 2018, “Arcturus Therapeutics to develop ARCT-810 for treatment of OTCD – Seeking Alpha” on January 02, 2019, “Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders – GlobeNewswire” with a publish date: July 09, 2018, “Arcturus Therapeutics Files Form 20-F Nasdaq:ARCT – GlobeNewswire” and the last “Arcturus Therapeutics (ARCT) Completes Merger with Alcobra (ADHD) and Commences Trading on Nasdaq Global Market – StreetInsider.com” with publication date: November 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.